Antimicrobial treatment of anaerobic infections

Bibliography

• Hecht DW. Anaerobes: antibiotic resistance, clinical significance, and the role of susceptibility testing. Anaerobe 2006;12:115-21
   PubMed Web of Science ®Google Scholar
• Kaide CG, Khandelwal S. Hyperbaric oxygen: applications in infectious disease. Emerg Med Clin North Am 2008;26:571-95
   PubMed Web of Science ®Google Scholar
• Barnes RC. Point: hyperbaric oxygen is beneficial for diabetic foot wounds. Clin Infect Dis 2006;43:188-92
   PubMed Web of Science ®Google Scholar
• Cimsit M, Uzun G, Yildiz S. Hyperbaric oxygen therapy as an anti-infective agent. Expert Rev Anti Infect Ther 2009;7:1015-26
   PubMed Web of Science ®Google Scholar
• Brook I. Microbiology and antimicrobial management of head and neck infections in children. In: Kappy MS, Accurso FJ, Barness LA, editors. Advances in pediatrics. Elsevier-Mosby, Philadelphia, PA; 2008. p. 305-25
   Google Scholar
• Brook I. Anaerobic infections diagnosis and management. A textbook. Informa Healthcare USA, Inc., New York; 2007
   Google Scholar
• Sweet RL. Treatment strategies for pelvic inflammatory disease. Expert Opin Pharmacother. 2009;10:823-37
   Google Scholar
• Mazuski JE, Solomkin JS. Intra-abdominal infections. Surg Clin North Am 2009;89:421-37
   PubMed Web of Science ®Google Scholar
• Finegold SM, George WL, Mulligan ME. Anaerobic infections. Disease a month. Volume 31. Yearbook Medical Publisher, Inc., Chicago; 1985
   Google Scholar
• Verklin RM, Mandell GL. Alteration of antibiotics by anaerobiosis. J Lab Clin Med 1977;89:65-71
   PubMed Web of Science ®Google Scholar
• Gorbach SL, Bartlett JG. Anaerobic infections. N Engl J Med 1974;290:1177-84
   PubMed Web of Science ®Google Scholar
• Singer E, Calvet L, Mory F, Monitoring of antibiotic resistance of gram negative anaerobes. Med Mal Infect 2008;38:256-63
   PubMedGoogle Scholar
• Glupczynski Y, Berhin C, Nizet H. Antimicrobial susceptibility of anaerobic bacteria in Belgium as determined by E-test methodology. Eur J Clin Microbiol Infect Dis 2009;28:261-7
   PubMed Web of Science ®Google Scholar
• Roh KH, Kim S, Kim CK, Resistance trends of Bacteroides fragilis group over an 8-year period, 1997 – 2004, in Korea. Korean J Lab Med 2009;29:293-8
   PubMedGoogle Scholar
• Seifert H, Dalhoff A; PRISMA Study Group. German multicentre survey of the antibiotic susceptibility of Bacteroides fragilis group and Prevotella species isolated from intra-abdominal infections: results from the PRISMA study. J Antimicrob Chemother 2010;65:2405-10
   PubMed Web of Science ®Google Scholar
• Snydman DR, Jacobus NV, McDermott LA, Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005 – 2007). Clin Infect Dis 2010;50(Suppl 1):S26-33
   PubMed Web of Science ®Google Scholar
• Labbe AC, Bourgault AM, Vincelette J, Trends in antimicrobial resistance among clinical isolates of the Bacteroides fragilis group from 1992 to 1997 in Montreal, Canada. Antimicrob Agents Chemother 1999;43:2517-19
   PubMed Web of Science ®Google Scholar
• Fernández Canigia L, Castello L, Di Martino A, Susceptibility trends of Bacteroides fragilis group isolates from Buenos Aires, Argentina. Rev Argent Microbiol 2007;39:156-60
   PubMedGoogle Scholar
• Nagy E, Urbán E, Nord CE; on behalf of the ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe: 20 years of experience. Clin Microbiol Infect 2011;17:371-9
   PubMed Web of Science ®Google Scholar
• Liu CY, Huang YT, Liao CH, Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. Antimicrob Agents Chemother 2008;52:3161-8
   PubMed Web of Science ®Google Scholar
• Finegold SM. Anaerobic bacteria in human disease. Academic Press, New York; 1977
   Google Scholar
• Goldstein EJC, Citron DM. Resistance trends in antimicrobial susceptibility of anaerobic bacteria. Clin Micro Newslett 2011;33:1-16
   Google Scholar
• Finegold SM. In vitro efficacy of beta-lactam/beta-lactamase inhibitor combinations against bacteria involved in mixed infections. Int J Antimicrob Agents 1999;12(Suppl 1):S9-14
   PubMed Web of Science ®Google Scholar
• Acuna C, Rabasseda X. Amoxicillin-sulbactam: a clinical and therapeutic review. Drugs Today (Barc) 2001;37:193-210
   PubMed Web of Science ®Google Scholar
• Sutter VL, Finegold SM. Susceptibility of anaerobic bacteria to carbenicillin, cefoxitin, and related drugs. J Infect Dis 1975;131:417-22
   PubMed Web of Science ®Google Scholar
• Fiedelman W, Webb CD. Clinical evaluation of carbenicillin in the treatment of infection due to anaerobic bacteria. Curr Ther Res Clin Exp 1975;18:441-51
   PubMed Web of Science ®Google Scholar
• Thadepalli H, Huang JT. Treatment of anaerobic infections: carbenicillin alone compared with clindamycin and gentamicin. Curr Ther Res 1977;22:549-57
   Web of Science ®Google Scholar
• Brook I. Carbenicillin in treatment of aspiration pneumonia in children. Curr Ther Res 1978;23:136-47
   Web of Science ®Google Scholar
• Brook I. Anaerobic isolates in chronic recurrent suppurative otitis media: treatment with carbenicillin alone and in combination with gentamicin. Infection 1979(5):247-51
   PubMedGoogle Scholar
• Tally FP, Jacobus NV, Bartlett JG, Gorbach SL. In vitro activity of penicillins against anaerobes. Antimicrob Agents Chemother 1975;7:413-14
   PubMed Web of Science ®Google Scholar
• Roy I, Bach V, Thadepalli H. In vitro activity of ticarcillin against anaerobic bacteria compared with that of carbenicillin and penicillin. Antimicrob Agents Chemother 1977;11:258-61
   PubMed Web of Science ®Google Scholar
• Powell LL, Wilson SE. The role of beta-lactam antimicrobials as single agents in treatment of intra-abdominal infection. Surg Infect 2000;1:57-63
   PubMedGoogle Scholar
• Jousimies-Somer H, Summanen P. Recent taxonomic changes and terminology update of clinically significant anaerobic gram-negative bacteria (excluding spirochetes). Clin Infect Dis 2002;35(Suppl 1):S17-21
   Google Scholar
• Jousimies-Somer HR, Summanen P, Baron EJ, Wadsworth-KTL anaerobic bacteriology manual. 6th edition. Star Publishing, Belmont, CA; 2002
   Google Scholar
• Brook I. Microbiology and management of abdominal infections. Dig Dis Sci 2008;53:2585-91
   PubMedGoogle Scholar
• Goldstein EJ. Intra-abdominal anaerobic infections: bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone, and desfluoroquinolone therapeutic agents. Clin Infect Dis 2002;35(Suppl 1):S106-111
   Google Scholar
• Hedberg M, Nord CE; ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe. Clin Microbiol Infect 2003;9:475-88
   PubMed Web of Science ®Google Scholar
• Lucasti C, Jasovich A, Umeh O, Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Clin Ther 2008;30:868-83
   PubMed Web of Science ®Google Scholar
• Goulenok TM, Majed K, Monchi M. Role and impact of carbapenem in nosocomial infections. Recent Pat Antiinfect Drug Discov 2011;6:45-53
   PubMedGoogle Scholar
• Bassetti M, Nicolini L, Esposito S, Current status of newer carbapenems. Curr Med Chem 2009;16:564-75
   PubMed Web of Science ®Google Scholar
• Nicolau DP. Pharmacokinetic and pharmacodynamic properties of meropenem. Clin Infect Dis 2008;47(Suppl 1):S32-40
   PubMed Web of Science ®Google Scholar
• Kattan JN, Villegas MV, Quinn JP. New developments in carbapenems. Clin Microbiol Infect 2008;14:1102-111
   PubMed Web of Science ®Google Scholar
• Keating GM, Perry CM. Ertapenem: a review of its use in the treatment of bacterial infections. Drugs 2005;65:2151-78
   PubMed Web of Science ®Google Scholar
• Paterson DL, Depestel DD. Doripenem. Clin Infect Dis 2009;49:291-8
   PubMed Web of Science ®Google Scholar
• Kasten MJ. Clindamycin, metronidazole, and chloramphenicol. Mayo Clin Proc 1999;74:825-33
   PubMed Web of Science ®Google Scholar
• Thadepalli H, Gorbach SL, Bartlett JG. Apparent failure of chloramphenicol in anaerobic infections. Obstet Gynecol Surv 1978;35:334-5
   Google Scholar
• Balbi HJ. Chloramphenicol: a review. Pediatr Rev 2004;25:284-8
   PubMed Web of Science ®Google Scholar
• Nau R, Sorgel F, Prange HW. Pharmacokinetic optimisation of the treatment of bacterial central nervous system infections. Clin Pharmacokinet 1998;35:223-46
   PubMed Web of Science ®Google Scholar
• Drutz DJ, Schaffner W, Hillman JW, Koenig MG. The penetration of penicillin and other antimicrobials into joint fluid. J Bone Joint Surg Am 1967;49:1415-21
   PubMed Web of Science ®Google Scholar
• Joiner KA, Lowe BR, Dzink JL, Bartlett JG. Antibiotic levels in infected and sterile subcutaneous abscesses in mice. J Infect Dis 1981;143:487-94
   PubMed Web of Science ®Google Scholar
• Goldstein EJ, Citron DM, Merriam CV. Linezolid activity compared to those of selected macrolides and other agents against aerobic and anaerobic pathogens isolated from soft tissue bite infections in humans. Antimicrob Agents Chemother 1999;43:1469-74
   PubMed Web of Science ®Google Scholar
• Williams JD, Maskell JP, Shain H, Comparative in-vitro activity of azithromycin, macrolides (erythromycin, clarithromycin and spiramycin) and streptogramin RP 59500 against oral organisms. J Antimicrob Chemother 1992;30:27-37
   PubMed Web of Science ®Google Scholar
• Sanai Y, Persson GR, Starr JR, Presence and antibiotic resistance of Porphyromonas gingivalis, Prevotella intermedia, and Prevotella nigrescens in children. J Clin Periodontol 2002;29:929-34
   PubMed Web of Science ®Google Scholar
• Finegold SM, Harada NE, Miller LG. Lincomycin activity against anaerobes and effect on normal human fecal flora. Antimicrob Agents Chemother (Bethesda) 1965(5):659-67
   PubMedGoogle Scholar
• Aldridge KE, Ashcraft D, Cambre K, Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species. Antimicrob Agents Chemother 2001;45:1238-43
   PubMed Web of Science ®Google Scholar
• Klainer AS. Clindamycin. Med Clin North Am 1987;71:1169-75
   PubMed Web of Science ®Google Scholar
• Paap CM, Nahata MC. Clinical pharmacokinetics of antibacterial drugs in neonates. Clin Pharmacokinet 1990;19:280-318
   PubMed Web of Science ®Google Scholar
• Feigin RD, Pickering LK, Anderson D, Clindamycin treatment of osteomyelitis and septic arthritis in children. Pediatrics 1975;55:213-23
   PubMed Web of Science ®Google Scholar
• Novak E, Wagner JG, Lamb DJ. Local and systemic tolerance, absorption and excretion of clindamycin hydrochloride after intramuscular administration. Int Z Klin Pharmakol Ther Toxikol 1970;3:201-8
   PubMedGoogle Scholar
• Panzer JD, Brown DC, Epstein WL, Clindamycin levels in various body tissues and fluids. J Clin Pharmacol New Drugs 1972;12:259-62
   PubMedGoogle Scholar
• Gorbach SL, Thadepalli H. Clindamycin in the treatment of pure and mixed anaerobic infections. Arch Intern Med 1974;134:87-92
   PubMedGoogle Scholar
• Gorbach SL. Antibiotics and Clostridium difficile. N Engl J Med 1999;341:1690-1
   PubMed Web of Science ®Google Scholar
• Mylonakis E, Ryan ET, Calderwood SB. Clostridium difficile – associated diarrhea: a review. Arch Intern Med 2001;161:525-33
   PubMed Web of Science ®Google Scholar
• Devenyi AG. Antibiotic-induced colitis. Semin Pediatr Surg 1995;4:215-20
   PubMedGoogle Scholar
• Berlatzky Y, Rubin SZ, Michel J, Use of clindamycin and gentamicin in pediatric colonic surgery. J Pediatr Surg 1976;11:94-83
   Google Scholar
• Brook I. Clindamycin in treatment of aspiration pneumonia in children. Antimicrob Agents Chemother 1979;15:342-4
   PubMedGoogle Scholar
• Brook I. Bacteriology and treatment of chronic otitis media in children. Laryngoscope 1979;89:1129-34
   PubMed Web of Science ®Google Scholar
• Brook I, Yocum P. Antimicrobial management of chronic sinusitis in children. J Laryngol Otol 1995;109:1159-62
   PubMed Web of Science ®Google Scholar
• Brook I, Lewis MA, Sandor GK, Clindamycin in dentistry: more than just effective prophylaxis for endocarditis?. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;100:550-8
   PubMed Web of Science ®Google Scholar
• Lofmark S, Edlund C, Nord CE. Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin Infect Dis 2010;50(Suppl 1):S16-23
   PubMedGoogle Scholar
• Rustia M, Shubik P. Experimental induction of hematomas, mammary tumors and other tumors with metronidazole in noninbred Sas: WRC (WT)BR rats. J Natl Cancer Inst 1979;63:863-8
   PubMed Web of Science ®Google Scholar
• Cohen SM, Erturk E, Von Esch AM, Carcinogenicity of 5-nitro-furans 5-nitromidazoles, 4-nitrobenzenes and related compounds. J Natl Cancer Inst 1973;51:403-17
   PubMed Web of Science ®Google Scholar
• Beard CM, Noller KL, O'Fallon WM, Lack of evidence for cancer due to use of metronidazole. N Engl J Med 1979;301:519-22
   PubMed Web of Science ®Google Scholar
• Celik A, Aras Ates N. The frequency of sister chromatid exchanges in cultured human peripheral blood lymphocyte treated with metronidazole in vitro. Drug Chem Toxicol 2006;29:85-94
   PubMed Web of Science ®Google Scholar
• Friedman GD, Jiang SF, Udaltsova N, Epidemiologic evaluation of pharmaceuticals with limited evidence of carcinogenicity. Int J Cancer 2009;125:2173-18
   PubMed Web of Science ®Google Scholar
• Brook I. Treatment of anaerobic infections in children with metronidazole. Dev Pharmacol Ther 1983;6:187-98
   PubMedGoogle Scholar
• Toft Sørensen H, Larsen H, Snitker Jensen E, Safety of metronidazole during pregnancy: a cohort study of risk of congenital abnormalities, preterm delivery and low birth weight in 124 women. J Antimicrob Chemother 1999;44:854-5
   PubMedGoogle Scholar
• Nord CE, Oprica C. Antibiotic resistance in Propionibacterium acnes. Microbiological and clinical aspects. Anaerobe 2006;12:207-10
   PubMed Web of Science ®Google Scholar
• Nicolau DP. Management of complicated infections in the era of antimicrobial resistance: the role of tigecycline. Expert Opin Pharmacother 2009;10:1213-22
   PubMed Web of Science ®Google Scholar
• Goldstein EJ, Citron DM, Merriam CV, Comparative in vitro susceptibilities of 396 unusual anaerobic strains to tigecycline and eight other antimicrobial agents. Antimicrob Agents Chemother 2006;50:3507-13
   PubMed Web of Science ®Google Scholar
• Appelbaum PC. Quinolone activity against anaerobes. Drugs 1999;58:60-4
   PubMed Web of Science ®Google Scholar
• Stein GE, Goldstein EJ. Fluoroquinolones and anaerobes. Clin Infect Dis 2006;42:1598-607
   PubMed Web of Science ®Google Scholar
• Blondeau JM, Sanche SE. Quinupristin/dalfopristin. Expert Opin Pharmacother 2002;3:1341-6
   PubMedGoogle Scholar
• Brook I. Pathogenicity and management of polymicrobial infections due to aerobic and anaerobic bacteria. Med Res Rev 1995;15:73-82
   PubMed Web of Science ®Google Scholar
• Concia E, Viscoli C. Antimicrobial management of intra-abdominal infections. J Chemother 2009;21(Suppl 1):39-43
   PubMedGoogle Scholar
• Holzheimer RG, Dralle H. Antibiotic therapy in intra-abdominal infections – a review on randomised clinical trials. Eur J Med Res 2001;30:277-91
   Google Scholar
• Tellado JM, Wilson SE. Empiric treatment of nosocomial intra-abdominal infections: a focus on the carbapenems. Surg Infect (Larchmt) 2005;6:329-43
   PubMedGoogle Scholar
• Sanabria A. Decision-making analysis for selection of antibiotic treatment in intra-abdominal infection using preference measurements. Surg Infect (Larchmt) 2006;7:453-62
   PubMedGoogle Scholar
• Laterre PF, Colardyn F, Delmee M, ; IDAB. Antimicrobial therapy for intra-abdominal infections: guidelines from the Infectious Disease Advisory Board (IDAB). Acta Chir Belg 2006;106:2-21
   PubMed Web of Science ®Google Scholar
• Marshall JC. Intra-abdominal infections. Microbes Infect 2004;6:1015-25
   PubMed Web of Science ®Google Scholar
• Giamarellou H, Kanellakopoulou K. Bacteriologic and therapeutic considerations in intra-abdominal surgical infections. Anaerobe 1997;3:207-112
   PubMed Web of Science ®Google Scholar
• Kaniga K, Flamm R, Tong SY, Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies. Antimicrob Agents Chemother 2010;54:2119-24
   PubMed Web of Science ®Google Scholar
• Burkhardt O, Derendorf H, Welte T. Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practice. Expert Opin Pharmacother 2007;8:237-56
   PubMed Web of Science ®Google Scholar
• Munckhof WJ, Carney J, Neilson G, Continuous infusion of ticarcillin-clavulanate for home treatment of serious infections: clinical efficacy, safety, pharmacokinetics and pharmacodynamics. Int J Antimicrob Agents 2005;25:514-22
   PubMed Web of Science ®Google Scholar
• Solomkin JS, Mazuski JE, Bradley JS, Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010;50:133-6
   PubMed Web of Science ®Google Scholar
• Brook I, Coolbaugh JC, Walker RI, Weiss E. Synergism between penicillin, clindamycin or metronidazole and gentamicin against species of Bacteroides melaninogenicus and fragilis groups. Antimicrob Agents Chemother 1984;25:71-7
   PubMed Web of Science ®Google Scholar
• Acar JF. Antibiotic synergy and antagonism. Med Clin North Am 2000;84:1391-406
   PubMed Web of Science ®Google Scholar
• Snydman DR, Jacobus NV, McDermott LA, National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends for 1997 – 2000. Clin Infect Dis 2002;35(Suppl 1):S126-34
   PubMedGoogle Scholar
• Bergan T, Fotland MH. In vitro interactions between metronidazole or tinidazole and co-trimoxazole on the effect against anaerobic bacteria. Scand J Gastroenterol Suppl 1984;19(Suppl):95-101
   Google Scholar
• Ralph ED, Amatnieks YE. Potentially synergistic antimicrobial combinations with metronidazole against Bacteroides fragilis. Antimicrob Agents Chemother 1980;17:379-82
   PubMed Web of Science ®Google Scholar
• Busch DF, Sutter VL, Finegold SM. Activity of combinations of antimicrobial agents against Bacteroides fragilis. J Infect Dis 1976;133-321-8
   Google Scholar
• Brook I. Metronidazole and spiramycin in abscesses caused by Bacteroides sp. Staphylococcus aureus in mice. J Antimicrob Chemother 1987;20:713-18
   PubMed Web of Science ®Google Scholar
• Videau D, Blanchard JC, Sebald M. Bucco-dental flora. Sensitivity to antibiotics and value of the spiramycin-metronidazole combination. Ann Microbiol (Paris) 1973;1248:505-16
   Google Scholar
• Ednie LM, Credito KL, Khantipong M, Synergic activity, for anaerobes, of trovafloxacin with clindamycin or metronidazole: chequerboard and time-kill methods. J Antimicrob Chemother 2000;45:633-8
   PubMed Web of Science ®Google Scholar
• Credito KL, Jacobs MR, Appelbaum PC. Anti-anaerobic activity of levofloxacin alone and combined with clindamycin and metronidazole. Diagn Microbiol Infect Dis 2000;38:181-3
   PubMed Web of Science ®Google Scholar
• Fass RJ, Rotilie CA, Prior RB. Interaction of clindamycin and gentamicin in vitro. Antimicrob Agents Chemother 1974;6.582-7
   PubMedGoogle Scholar
• Okubadejo OA, Allen J. Combined activity of clindamycin and gentamicin on Bacteroides fragilis and other bacteria. J Antimicrob Chemother 1975;1:403-9
   PubMedGoogle Scholar
• Brook I, Walker RI. Interaction between penicillin, clindamycin or metronidazole and gentamicin against species of clostridia and anaerobic and facultative anaerobic Gram-positive cocci. J Antimicrob Chemother 1985;15:31-7
   PubMed Web of Science ®Google Scholar
• Bryan LE, Kowand SK, Den Elzen HM. Mechanisms of aminoglycoside antibiotic resistance in anaerobic bacteria: Clostridium perfringens and Bacteroides fragilis. Antimicrob Agents Chemother 1979;15:7-13
   PubMedGoogle Scholar
• Delgado G Jr, Barletta JF, Kanji S, Characteristics of prophylactic antibiotic strategies after penetrating abdominal trauma at a level I urban trauma center: a comparison with the East guidelines. J Trauma 2002;53:673-8
   PubMedGoogle Scholar
• Petersen K, Waterman P. Prophylaxis and treatment of infections associated with penetrating traumatic injury. Expert Rev Anti Infect Ther 2011;9:81-96
   PubMed Web of Science ®Google Scholar
• Gerding DN, Johnson S. Management of Clostridium difficile infection: thinking inside and outside the box. Clin Infect Dis 2010;51:1306-13
   PubMed Web of Science ®Google Scholar
• Brook I. Actinomycosis: diagnosis and management. South Med J 2008;101:1019-23
   PubMed Web of Science ®Google Scholar